Optimus Pharma granted permission for Restricted Use under Emergency Situation from the DCGI for its COVID-19 pill MOLNUPIRAVIR

Read Time:2 Minute, 14 Second

Hyderabad (Telangana) [India], December 28: Hyderabad, Optimus Pharma announced launching of their front line COVID-19 medication Molnupiravir in the Indian market, as they have received permission the restricted emergency use for Covid-19 drug.  Optimus Pharma successfully completed the Phase 3 Clinical Trial on 1218 subjects across 29 geographical study sites all over India. “We want to cover maximum demographic diversity into our trial in order to obtain data across the different geographical regions of the country and conclusive evidence that Molnupiravir is able to bring about viral load reduction over 5 days of treatment duration,” said Chairman and Managing Director of Optimus Pharma, Dr D Srinivasa Reddy. Optimus Pharma has developed the API in the house at its R&D centre in Hyderabad. Optimus Pharma has revealed highly promising results of the drug in its ability to reduce viral load and bring out significant symptomatic improvement in patients’ health.

It is to be noted that in the Clinical Trial, Molnupiravir was administered to the subjects along with Standard of Care (SoC) medication as per the approved protocol by CDSCO. The trial was successful in establishing a clinical significant results of ‘Molnupiravir + SoC’ over ‘SoC’ arm.

  • Rate of hospitalization was less in Molnupiravir+SoC when compared to SoC group.
  • Greater clinical improvement observed in Molnupiravir + SoC arm compared to SOC alone by Day 5 and Day 10.
  • Proportion of subjects with RT-PCR negativity at Day 5 and Day 10 was statistically significant in Molnupiravir + SoC arm.
  • Higher viral load reduction was observed in Molnupiravir+ SoC arm
  • No serious safety concerns observed with Molnupiravir in overall study duration, no mortality was observed in the trial across both the arms

 Molnupiravir is administered as an 800 mg dose by orally consuming four capsules of 200mg twice a day. Upon oral administration, Molnupiravir, being a prodrug, is metabolized into its active form and converted into its triphosphate (TP) form. The TP form of Molnupiravir is incorporated into RNA and inhibits the action of viral RNA-dependent RNA polymerase. This results in the termination of RNA transcription, thereby significantly reducing viral replication.

Optimus Pharma is ready with a commercial quantity of the drug to cater to the unmet medical need of the nation. It is with heartfelt gratitude that we thank the Subject Expert Committee of the CDSCO and the DCGI for their valuable recommendations and guidance for the Clinical Trial, thereby making this project a huge success, said Dr D. Srinivas Reddy (MD Optimus) in his statement to the press. Optimus Pharma is committed to consistently integrating quality, affordability and reliability into their products and ensuring timely access to life-saving medication to whomsoever is in need.

Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %

Average Rating

5 Star
30%
4 Star
20%
3 Star
10%
2 Star
0%
1 Star
40%

13 thoughts on “Optimus Pharma granted permission for Restricted Use under Emergency Situation from the DCGI for its COVID-19 pill MOLNUPIRAVIR

  1. Do you mind if I quote a few of your posts as long as I provide credit and sources
    back to your webpage? My blog site is in the exact same area of interest as yours and my users would definitely
    benefit from some of the information you present here.

    Please let me know if this ok with you. Thanks
    a lot!

  2. Heya i am for the primary time here. I found this board and I
    find It really helpful & it helped me out a lot.
    I am hoping to offer something back and aid others such as you
    aided me.

  3. Hi there! I know this is somewhat off topic but
    I was wondering if you knew where I could get a captcha plugin for
    my comment form? I’m using the same blog platform
    as yours and I’m having problems finding one? Thanks
    a lot!

  4. This is very interesting, You are an overly skilled blogger.
    I have joined your rss feed and look forward to in the hunt for more of your
    fantastic post. Also, I have shared your site in my social networks

  5. These are actually fantastic ideas in on the topic of blogging.
    You have touched some fastidious points here. Any way keep up wrinting.

  6. I don’t even understand how I finished up right here, but I thought
    this publish was once great. I do not recognise who you might be
    however definitely you’re going to a famous blogger in case you aren’t already.
    Cheers!

  7. Fantastic beat ! I would like to apprentice while you
    amend your website, how can i subscribe for a blog site?
    The account helped me a acceptable deal. I had been a little bit acquainted of this your broadcast
    provided bright clear idea

    Also visit my page tracfone

Leave a Reply

Your email address will not be published.

Previous post Candid chat with Mrs India Earth Poonam Chaubey
Next post Babubhai Sweets From Surat Sets World Record For Biggest Ghari 15 Kg and Smallest Ghari 15 Gm